Cellectar Biosciences, a Madison company working on cancer-fighting compounds, reported a net loss of $5.5 million, or $7.03 a share for the 2015 fiscal year, down from a net loss of $8.1 million, or $17.53 a share, for 2014. Read the full Wisconsin State Journal story here.
- InsideWis: Healthy startup communities benefit when entrepreneurs cash outOctober 17, 2019
- Achieving effectiveness at work, home topic at Nov. 5 W·O·M·E·N reception in MadisonOctober 16, 2019
- InWisconsin: Early Stage Symposium connects young companies with investorsOctober 15, 2019
- Fox11News: The business of papermaking: ‘Far from a dying industry’October 14, 2019
- Law Clinic’s co-founder Anne Smith to accept ‘Triple E’ award Nov. 6 at Early Stage eventOctober 11, 2019